{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(9)"],"submitter":["Boisteau E"],"pubmed_abstract":["<h4>Introduction</h4>Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy.<h4>Patients and methods</h4>We focused on patients who received 12 cycles of FOLFIRINOX (arm A, N = 88) or 8 cycles of FOLFIRINOX followed by LV5FU2 maintenance in controlled patients (arm B, N = 91) from the PRODIGE-35 trial. Prognostic factors and predictors of efficiency were identified by using Cox regression. Median progression-free survival (PFS), overall survival (OS), and time to deterioration of quality of life (TTD-QoL) were evaluated.<h4>Results</h4>Poor independent prognostic factors were primary tumor in place, age <65 years and the presence of liv"],"journal":["The oncologist"],"pagination":["e1149-e1158"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11379635"],"repository":["biostudies-literature"],"pubmed_title":["Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer."],"pmcid":["PMC11379635"],"pubmed_authors":["Bourgeois V","Boulat","Bernard P","Bouche O","Taieb J","Desgrippes R","Baba-Hamed N","Lecaille C","Remy S","Granger V","Plastaras L","Pigui A","Baconnier M","Belletier","Bouhier-Leporrier K","Walter T","Cattan S","Follana P","Cavaglione G","Rinaldi Y","Villing AL","Hollebecque A","Petorin C","Devaure I","Hebbar M","Andrau P","Farneti D","Thomas Marques L","Bonnet I","Williet N","Lledo G","Le Malicot K","Breysacher G","Locher C","Desauw","Desrame J","Duluc M","Lagasse JP","Baize N","Dupont Gossart AC","Ceban T","Sverdlin R","Evesque L","PRODIGE 35 Investigator/Collaborators","Boisteau E","Corbinais S","Hocine F","Ducreux M","Lecomte T","Vimal-Baguet A","Gigout J","Simon M","Aparicio T","Ferte C","Boige V","Topolski A","Audemar F","Lombard-Bohas C","Mary F","Dahan L","Sefrioui D","Arsenii N","Guilngar A","Norguet E","Moullet I","Deplanque G","Le Roy F","Bignon AL","Jouve JL","Meunier J","Lepage C","Francois E","Romano O","Charlois T","Seitz JF","Ezenfis J","Pezet D","Cumin I","Cornila C","Michel P","Escande A","Molin Y","Barriere N","Guillet M","Sibertin-Blanc C","Rebischung C","Foll L","Turpin A","Malka D","Dupont Kazma L","Duchmann JC","Artru P","Legoux JL","Coufon C","Bedenne L","Burtin P","Zaanan A","Durand A","Staudacher L","Talarmin M","Pracht M","Berdah S","Lievre A","Bachet JB","Le Sourd S"],"additional_accession":[]},"is_claimable":false,"name":"Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.","description":"<h4>Introduction</h4>Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this strategy.<h4>Patients and methods</h4>We focused on patients who received 12 cycles of FOLFIRINOX (arm A, N = 88) or 8 cycles of FOLFIRINOX followed by LV5FU2 maintenance in controlled patients (arm B, N = 91) from the PRODIGE-35 trial. Prognostic factors and predictors of efficiency were identified by using Cox regression. Median progression-free survival (PFS), overall survival (OS), and time to deterioration of quality of life (TTD-QoL) were evaluated.<h4>Results</h4>Poor independent prognostic factors were primary tumor in place, age <65 years and the presence of liv","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-07-15T05:35:22.189Z","creation":"2025-04-05T13:58:07.146Z"},"accession":"S-EPMC11379635","cross_references":{"pubmed":["39235326"],"doi":["10.1093/oncolo/oyae079"]}}